Dale  Chappell net worth and biography

Dale Chappell Biography and Net Worth

Insider of Humanigen
Dr. Dale Michael Chappell M.D. serves as Chief Scientific Officer of the Company. Dr. Chappell began his career as a Howard Hughes Medical Institute fellow at the National Cancer Institute where he studied tumor immunology and published in the field of T-cell therapy, immunology pathways, and GM-CSF, giving him clear insights into the development and execution of our business strategy. He is also the founder of Black Horse Capital with decades of biotechnology investment experience.

What is Dale Chappell's net worth?

The estimated net worth of Dale Chappell is at least $0.00 as of May 20th, 2022. Dr. Chappell owns 8,675,081 shares of Humanigen stock worth more than $0 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Chappell may own. Additionally, Dr. Chappell receives a salary of $410,000.00 as Insider at Humanigen. Learn More about Dale Chappell's net worth.

How old is Dale Chappell?

Dr. Chappell is currently 54 years old. There are 1 older executives and no younger executives at Humanigen. The oldest executive at Humanigen is Dr. Cameron Durrant M.D., MBA, Chairman, CEO & Acting CFO, who is 64 years old. Learn More on Dale Chappell's age.

What is Dale Chappell's salary?

As the Insider of Humanigen, Inc., Dr. Chappell earns $410,000.00 per year. The highest earning executive at Humanigen is Dr. Cameron Durrant M.D., MBA, Chairman, CEO & Acting CFO, who commands a salary of $640,000.00 per year. Learn More on Dale Chappell's salary.

How do I contact Dale Chappell?

The corporate mailing address for Dr. Chappell and other Humanigen executives is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. Humanigen can also be reached via phone at 650-243-3100 and via email at [email protected]. Learn More on Dale Chappell's contact information.

Has Dale Chappell been buying or selling shares of Humanigen?

Dale Chappell has not been actively trading shares of Humanigen within the last three months. Most recently, on Friday, May 20th, Dale Chappell bought 545,488 shares of Humanigen stock. The stock was acquired at an average cost of $2.23 per share, with a total value of $1,216,438.24. Following the completion of the transaction, the insider now directly owns 8,675,081 shares of the company's stock, valued at $19,345,430.63. Learn More on Dale Chappell's trading history.

Who are Humanigen's active insiders?

Humanigen's insider roster includes Dale Chappell (Insider), Cameron Durrant (CEO), and Edward Jordan (Insider). Learn More on Humanigen's active insiders.

Dale Chappell Insider Trading History at Humanigen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2022Buy545,488$2.23$1,216,438.248,675,081View SEC Filing Icon  
5/18/2022Buy173,700$1.96$340,452.008,066,575View SEC Filing Icon  
3/11/2022Buy1,000,000$3.00$3,000,000.00View SEC Filing Icon  
8/11/2021Sell109,647$17.07$1,871,674.29View SEC Filing Icon  
7/28/2021Sell9,692$17.04$165,151.68View SEC Filing Icon  
7/23/2021Sell5,584$17.04$95,151.36View SEC Filing Icon  
7/21/2021Sell132,764$17.14$2,275,574.96View SEC Filing Icon  
7/14/2021Sell15,177$17.06$258,919.62View SEC Filing Icon  
7/8/2021Sell48,010$17.17$824,331.70View SEC Filing Icon  
6/25/2021Sell1,000,000$17.80$17,800,000.00View SEC Filing Icon  
6/23/2021Sell133,126$18.28$2,433,543.28View SEC Filing Icon  
6/18/2021Sell402,480$18.50$7,445,880.00View SEC Filing Icon  
6/16/2021Sell158,486$19.41$3,076,213.26View SEC Filing Icon  
6/4/2021Sell127,084$18.46$2,345,970.64View SEC Filing Icon  
6/2/2021Sell76,126$19.01$1,447,155.26View SEC Filing Icon  
2/27/2018Buy32,028,669$0.09$2,882,580.21View SEC Filing Icon  
See Full Table

Dale Chappell Buying and Selling Activity at Humanigen

This chart shows Dale Chappell's buying and selling at Humanigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humanigen Company Overview

Humanigen logo
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

3,300 shs

Average Volume

3,262,400 shs

Market Capitalization

$24,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A